Related Experiment Video

Updated: Aug 13, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

[HLA and acetylcholine receptor antibody in patients with myasthenia gravis]

W Xu1

  • 1Department of Neurology, West China University of Medical Sciences, Chengdu.

Zhonghua Shen Jing Jing Shen Ke Za Zhi = Chinese Journal of Neurology and Psychiatry
|June 1, 1992
PubMed

Insights

This study reveals a strong association between Human Leukocyte Antigen (HLA) Bw46/Cx46 and myasthenia gravis (MG). Patients with these HLA antigens show lower acetylcholine receptor antibody (AchRab) titers, suggesting distinct MG subtypes.

Area of Science:

  • Immunogenetics
  • Neurology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
  • Human Leukocyte Antigen (HLA) and acetylcholine receptor antibody (AchRab) titers are key biomarkers in MG.
  • Understanding genetic associations can refine disease classification and treatment.

Purpose of the Study:

  • To investigate the association between specific HLA antigens (Bw46, Cx46) and AchRab titers in myasthenia gravis patients.
  • To explore potential clinical and serological differences between patient subgroups based on HLA status.

Main Methods:

  • Serum samples from 106 myasthenia gravis patients were analyzed for HLA and AchRab titers.
  • 93 patients underwent both HLA and AchRab assays.
  • Statistical analysis compared AchRab levels between patients with and without Bw46/Cx46 antigens.

Main Results:

  • A significant association was found between HLA Bw46/Cx46 antigens and myasthenia gravis.
  • Patients positive for Bw46/Cx46 exhibited significantly lower geometric mean AchRab titers (2.99) compared to negative patients (4.74, P < 0.05).
  • Two distinct patient groups emerged: one with ocular onset, childhood/adolescent onset, low AchRab, and HLA Bw46/Cx46 association; the other with generalized MG, adult onset, high AchRab, and no HLA association.

Conclusions:

  • Myasthenia gravis patients can be stratified into two groups based on clinical presentation, AchRab levels, and HLA Bw46/Cx46 antigen status.
  • The findings suggest that HLA Bw46/Cx46 positivity may indicate a specific subtype of MG with distinct immunological and clinical characteristics.

More Related Videos

Antibody Binding Specificity for Kappa (V&#954;) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Antigenic Liposomes for Generation of Disease-specific Antibodies10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

Related Concept Videos

Muscle Contraction01:10

Muscle Contraction

In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive muscle...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...